Charles G. Drake

Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy

Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates

A draft map of the human proteome

Immune Inhibitory Molecules LAG-3 and PD-1 Synergistically Regulate T-cell Function to Promote Tumoral Immune Escape

Inflammation in prostate carcinogenesis

Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial

Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity

Role of LAG-3 in Regulatory T Cells

Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma

<scp>LAG</scp>3 (<scp>CD</scp>223) as a cancer immunotherapy target